ArticleNature communications2021
A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 40 citations in OpenAlex.
- A G-Quadruplex-Activated Near-Infrared Chemiluminescent Probe for In Situ Hepatic Imaging of the Hepatitis C Virus Genome.Angewandte Chemie (International ed. in English) · 2026Article
- Loss of Mast cells and histaminergic signaling link diet to platelet-mediated NETosis and mammary cancer recurrence.bioRxiv : the preprint server for biology · 2026Article
- Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole.Hepatology (Baltimore, Md.) · 2026Article
- Article
- Oxidative stress biomarkers for assessing the synergistic toxicity of emamectin benzoate and cyantraniliprole on liver function.Scientific reports · 2025Article
- Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer.JHEP reports : innovation in hepatology · 2025Article
- Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.Gut and liver · 2025Review
- Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis.Gastroenterology · 2025Article
- Current and emerging strategies for the prevention of hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2025Review
- A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development.Nature communications · 2025Article
- Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy.Scientific reports · 2025Article
- Article
- Article
- An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection.Nature communications · 2024Article
- Scalable production of homogeneous cardiac organoids derived from human pluripotent stem cells.Cell reports methods · 2023Article
- Reconstruction of the regulatory hypermethylation network controlling hepatocellular carcinoma development during hepatitis C viral infection.Journal of integrative bioinformatics · 2023Article
- Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.World journal of gastroenterology · 2023Review
- Functional biomaterials for biomimetic 3D in vitro tumor microenvironment modeling.In vitro models · 2023Review
- [Overexpression of CLEC5A inhibits cell proliferation and metastasis and reverses epithelial-mesenchymal transition in hepatocellular carcinoma].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Hepatocellular Carcinoma Chemoprevention with Generic Agents.Seminars in liver disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors at 16 institutions in 5 countries.
Emilie CrouchetInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Simonetta BandieraInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Naoto FujiwaraLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-4109-3421
Shen LiDivision of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Hussein El SaghireInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Mirian Fernández-VaqueroDivision of Chronic Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany.
Tobias RiedlDivision of Chronic Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany.
Xiaochen SunLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hadassa HirschfieldLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Frank JühlingInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Shijia ZhuLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-2368-2361
Natascha RoehlenInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Clara PonsollesInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Laura HeydmannInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Antonio SavianoInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Tongqi QianLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Anu VenkateshLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Joachim LupbergerInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.ORCID 0000-0003-3996-3907
Eloi R VerrierInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.ORCID 0000-0002-9022-5611
Mozhdeh SojoodiDivision of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Marine A OudotInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
François H T DuongInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Ricard MasiaDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Lan WeiDivision of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Christine ThumannInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Sarah C DurandInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Victor González-MotosInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Danijela HeideDivision of Chronic Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany.
Jenny HetzerDivision of Chronic Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany.
Shigeki NakagawaLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Atsushi OnoDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0002-2482-945X
Won-Min SongDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.ORCID 0000-0003-0948-119X
Takaaki HigashiDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Roberto SanchezDepartment of Pharmacological Sciences and Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Rosa S KimDivision of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
C Billie BianDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Karun KianiDepartment of Neurology, Harvard Medical School, Boston, MA, USA.
Tom CroonenborghsDepartment of Neurology, Harvard Medical School, Boston, MA, USA.
Aravind SubramanianDepartment of Neurology, Harvard Medical School, Boston, MA, USA.
Raymond T ChungLiver Center and Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Beate K StraubInstitute of Pathology, University Medicine, Johannes Gutenberg University, Mainz, Germany.
Detlef SchuppanInstitute for Translational Immunology and Research Center for Immunotherapy (FZI), Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany.
Maliki AnkavayUniversity of Lille, CNRS, Inserm, CHU Lille, Pasteur Institute of Lille, U1019-UMR 8204-CIIL- Center for Infection and Immunity of Lille, Lille, France.
Laurence CocquerelUniversity of Lille, CNRS, Inserm, CHU Lille, Pasteur Institute of Lille, U1019-UMR 8204-CIIL- Center for Infection and Immunity of Lille, Lille, France.
Evelyne SchaefferCNRS UPR3572 Immunopathologie et Chimie Thérapeutique, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France.
Nicolas GoossensDivision of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland.
Anna P KohLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Milind MahajanDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Venugopalan D NairDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.ORCID 0000-0002-8231-6230
Ganesh GunasekaranRecanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Myron E SchwartzRecanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.ORCID 0000-0002-9113-886X
Nabeel BardeesyMassachusetts General Hospital Cancer Center; Harvard Medical School, Cambridge St. CPZN 4216, Boston, MA, USA.ORCID 0000-0003-3867-0416
Alex K ShalekBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-5670-8778
Orit Rozenblatt-RosenBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
Aviv RegevBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-3293-3158
Emanuele FelliInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Patrick PessauxInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Kenneth K TanabeDivision of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mathias HeikenwälderDivision of Chronic Inflammation and Cancer, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-3135-2274
Catherine SchusterInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.ORCID 0000-0001-7281-4511
Nathalie PochetDepartment of Neurology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1820-5656
Mirjam B ZeiselInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.ORCID 0000-0003-1606-0131
Bryan C FuchsDivision of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Bryan.Fuchs@ferring.com.ORCID 0000-0002-2149-3081
Yujin HoshidaLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. Yujin.Hoshida@UTSouthwestern.edu.ORCID 0000-0001-9430-1426
Thomas F BaumertInstitut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France. thomas.baumert@unistra.fr.ORCID 0000-0002-8864-2168
Inserm · FRHarvard University · USThe University of Texas Southwestern Medical Center · USIcahn School of Medicine at Mount Sinai · USBroad Institute · USGerman Cancer Research Center · DECentre National de la Recherche Scientifique · FRBeth Israel Deaconess Medical Center · USDiscovery Institute · USHiroshima University · JPJohannes Gutenberg University Mainz · DEKumamoto University · JPMassachusetts General Hospital · USSouthwestern Medical Center · USUniversité Claude Bernard Lyon 1 · FRUniversity Hospital of Geneva · CH
Funding
Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5MMolecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6MThe Role of EGF in Human Hepatocellular TransformationK01CA140861 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUCHS, BRYAN CHRISTOPHER · 2009 to 2013
$710kIntegrative genomic framework for dissecting regulatory mechanisms underlying hepatocellular carcinomaR21CA209940 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI POCHET, NATHALIE · 2017 to 2018
$402kSpatial and temporal profiling to unravel the host cell responses to hepatitis B virus infectionR03AI131066 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI POCHET, NATHALIE · 2018 to 2019
$181kNCI NIH HHS K01 CA140861NCI NIH HHS R01 CA233794NCI NIH HHS R21 CA209940NIAID NIH HHS R03 AI131066NIDDK NIH HHS R01 DK099558
Abstract
Chronic liver disease and hepatocellular carcinoma (HCC) are life-threatening diseases with limited treatment options. The lack of clinically relevant/tractable experimental models hampers therapeutic discovery. Here, we develop a simple and robust human liver cell-based system modeling a clinical prognostic liver signature (PLS) predicting long-term liver disease progression toward HCC. Using the PLS as a readout, followed by validation in nonalcoholic steatohepatitis/fibrosis/HCC animal models and patient-derived liver spheroids, we identify nizatidine, a histamine receptor H2 (HRH2) blocker, for treatment of advanced liver disease and HCC chemoprevention. Moreover, perturbation studies combined with single cell RNA-Seq analyses of patient liver tissues uncover hepatocytes and HRH2
Indexed as
Drug DiscoveryModels, BiologicalAnimalsCarcinogenesisCarcinoma, HepatocellularCell Line, TumorChemopreventionCohort StudiesCyclic AMPCyclic AMP Response Element-Binding ProteinDisease Models, AnimalGene Expression Regulation, NeoplasticHEK293 CellsHepacivirusHepatitis CHepatocytesCyclic AMPCyclic AMP Response Element-Binding ProteinNizatidine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.